$1.93 Billion is the total value of NEA Management Company, LLC's 39 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 16.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TSRO | TESARO INC | $863,623,000 | +90.9% | 10,275,113 | 0.0% | 44.82% | +49.2% | |
| GRPN | Sell | GROUPON INC | $107,607,000 | -38.9% | 33,109,905 | -25.0% | 5.58% | -52.3% |
| SENS | SENSEONICS HOLDINGS INC | $103,372,000 | +37.4% | 26,303,189 | 0.0% | 5.36% | +7.4% | |
| ARDX | ARDELYX INC | $102,950,000 | +12.4% | 11,792,631 | 0.0% | 5.34% | -12.2% | |
| DERM | DERMIRA INC | $102,569,000 | +41.4% | 3,506,649 | 0.0% | 5.32% | +10.5% | |
| ADAP | ADAPTIMMUNE THERAPEUTICSadr | $80,530,000 | +0.2% | 9,880,999 | 0.0% | 4.18% | -21.6% | |
| EPZM | EPIZYME INC | $64,111,000 | -15.5% | 6,260,851 | 0.0% | 3.33% | -34.0% | |
| GLYC | GLYCOMIMETICS INC | $62,407,000 | +22.0% | 8,584,128 | 0.0% | 3.24% | -4.7% | |
| NVRO | NEVRO CORP | $48,713,000 | +31.1% | 660,428 | 0.0% | 2.53% | +2.5% | |
| LOXO | LOXO ONCOLOGY INC | $41,543,000 | -15.2% | 1,792,207 | 0.0% | 2.16% | -33.7% | |
| CRCM | CARE COM INC | $38,088,000 | +89.9% | 3,260,989 | 0.0% | 1.98% | +48.4% | |
| PTI | PROTEOSTASIS THERAPEUTICS INC | $37,545,000 | +25.8% | 3,095,240 | 0.0% | 1.95% | -1.6% | |
| LXRX | LEXICON PHARMACEUTICALS INC | $34,186,000 | +20.1% | 2,382,286 | 0.0% | 1.77% | -6.2% | |
| ELGX | ENDOLOGIX INC | $31,028,000 | +49.0% | 2,490,204 | 0.0% | 1.61% | +16.5% | |
| HIVE | AEROHIVE NETWORKS INC | $30,991,000 | +32.7% | 4,681,455 | 0.0% | 1.61% | +3.7% | |
| TRVN | TREVENA INC | $24,014,000 | -23.8% | 3,811,691 | 0.0% | 1.25% | -40.5% | |
| AKAOQ | New | ACHAOGEN INC | $17,870,000 | – | 4,715,128 | +100.0% | 0.93% | – |
| EXEL | EXELIXIS INC | $17,237,000 | +95.3% | 2,207,000 | 0.0% | 0.90% | +52.7% | |
| CLVS | CLOVIS ONCOLOGY INC | $15,639,000 | -28.5% | 1,139,890 | 0.0% | 0.81% | -44.1% | |
| MIRN | MIRNA THERAPEUTICS INC | $12,673,000 | -2.5% | 2,974,811 | 0.0% | 0.66% | -23.8% | |
| CASC | New | CASCADIAN THERAPEUTICS INC | $10,105,000 | – | 10,750,000 | +100.0% | 0.52% | – |
| AVEO | New | AVEO PHARMACEUTICALS INC | $9,948,000 | – | 10,362,694 | +100.0% | 0.52% | – |
| SBBP | STRONGBRIDGE BIOPHARMA PLC | $8,522,000 | -12.7% | 2,141,308 | 0.0% | 0.44% | -31.8% | |
| TCON | TRACON PHARMACEUTICALS INC | $8,277,000 | -37.3% | 1,889,652 | 0.0% | 0.43% | -51.0% | |
| RIGL | RIGEL PHARMACEUTICALS INC | $7,232,000 | +7.2% | 3,243,150 | 0.0% | 0.38% | -16.3% | |
| AUPH | AURINIA PHARMACEUTICALS INC | $7,055,000 | -4.8% | 2,546,843 | 0.0% | 0.37% | -25.6% | |
| AKTX | New | AKARI THERAPEUTICS PLCadr | $6,100,000 | – | 452,167 | +100.0% | 0.32% | – |
| ZHNE | ZHONE TECHNOLOGIES INC | $5,690,000 | -25.6% | 4,781,290 | 0.0% | 0.30% | -41.9% | |
| ARQL | ARQULE INC | $4,789,000 | +18.7% | 2,520,316 | 0.0% | 0.25% | -7.1% | |
| SNSS | SUNESIS PHARMACEUTICALS INC | $4,284,000 | +1.9% | 7,789,644 | 0.0% | 0.22% | -20.4% | |
| ABIO | ARCA BIOPHARMA INC | $4,235,000 | -16.4% | 1,460,209 | 0.0% | 0.22% | -34.5% | |
| CSBR | CHAMPIONS ONCOLOGY INC | $3,359,000 | -40.9% | 1,562,500 | 0.0% | 0.17% | -54.0% | |
| ZSAN | ZOSANO PHARMA CORP | $2,741,000 | -44.8% | 2,158,543 | 0.0% | 0.14% | -57.0% | |
| ROKA | ROKA BIOSCIENCE INC | $1,836,000 | -17.4% | 3,220,433 | 0.0% | 0.10% | -35.8% | |
| OREX | Sell | OREXIGEN THERAPEUTICS INC | $1,595,000 | -23.2% | 370,900 | -90.0% | 0.08% | -39.9% |
| CERC | CERECOR INC | $1,310,000 | -41.0% | 595,435 | 0.0% | 0.07% | -53.7% | |
| AGRX | AGILE THERAPEUTICS PLC | $1,016,000 | +22.6% | 133,488 | 0.0% | 0.05% | -3.6% | |
| CBIO | CATALYST BIOSCIENCES INC | $992,000 | -9.5% | 652,380 | 0.0% | 0.05% | -30.1% | |
| PRTK | Sell | PARATEK PHARMACEUTICALS INC | $921,000 | -51.4% | 66,245 | -47.0% | 0.05% | -61.9% |
| Exit | AKARI THERAPEUTICS PLCadr | $0 | – | -438,780 | -100.0% | -0.41% | – | |
| OPWR | Exit | OPOWER INC | $0 | – | -8,997,290 | -100.0% | -4.07% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-05
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GLYCOMIMETICS INC | 39 | Q3 2023 | 7.6% |
| AURINIA PHARMACEUTICALS INC | 37 | Q3 2023 | 5.0% |
| CHAMPIONS ONCOLOGY INC | 33 | Q3 2023 | 1.2% |
| LEXICON PHARMACEUTICALS INC | 32 | Q3 2023 | 2.0% |
| ADAPTIMMUNE THERAPEUTICS PLC | 31 | Q3 2023 | 9.3% |
| TREVENA INC | 31 | Q3 2021 | 3.3% |
| AKARI THERAPEUTICS PLC | 31 | Q2 2023 | 0.3% |
| ARDELYX INC | 29 | Q3 2021 | 11.9% |
| RIGEL PHARMACEUTICALS INC | 29 | Q2 2020 | 0.6% |
| EPIZYME INC | 28 | Q1 2020 | 9.6% |
View NEA Management Company, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-10 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-12 |
View NEA Management Company, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.